New dosing strategy aims to tame blood cancer with fewer side effects
NCT ID NCT03961672
Summary
This study is testing whether giving the cancer drug duvelisib on an on-and-off schedule works as well as continuous dosing for people with recurrent chronic lymphocytic leukemia or small lymphocytic lymphoma. The goal is to see if this intermittent approach can control the cancer while causing fewer severe side effects. The trial involves 15 adults whose cancer has returned or stopped responding to prior treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
City of Hope Medical Center
Duarte, California, 91010, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
OHSU Knight Cancer Institute
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.